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Abstract
Several oncogene and tumor-suppressor gene prod-
ucts are known substrates for the calpain family of
cysteine proteases, and calpain is required for trans-
formation by v-src and tumor invasion. Thus, we have
now addressed whether calpain is generally associ-
ated with transformation and how calpain contributes
to oncogene function. Our results demonstrate that
calpain activity is enhanced upon transformation
induced by the v-Src, v-Jun, v-Myc, k-Ras, and v-Fos
oncoproteins. Furthermore, elevated calpain activity
commonly promotes focal adhesion remodelling, dis-
ruption of actin cytoskeleton, morphological trans-
formation, and cell migration, although proteolysis of
target substrates (such as focal adhesion kinase, talin,
and spectrin) is differently specified by individual
oncoproteins. Interestingly, v-Fos differs from other
common oncoproteins in not requiring calpain activity
for actin/adhesion remodelling or migration of v-Fos
transformed cells. However, anchorage-independent
growth of all transformed cells is sensitive to calpain
inhibition. In addition, elevated calpain activity con-
tributes to oncogene-induced apoptosis associated
with transformation by v-Myc. Taken together, these
studies demonstrate that calpain activity is necessary
for full cellular transformation induced by common
oncoproteins, but has distinct roles in oncogenic
events induced by individual transforming proteins.
Thus, targeting calpain activity may represent a useful
general strategy for interfering with activated proto-
oncogenes in cancer cells.
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Introduction
The calpains represent a highly conserved family of intra-
cellular, nonlysosomal, calcium-dependent cysteine pro-
teases. Calpain activity in vivo is tightly regulated by its
ubiquitously expressed endogenous inhibitor, calpastatin
[1–3]. The calpains cleave a broad spectrum of cellular
proteins. Thus, the calpain–calpastatin proteolytic system
represents a major mediator of posttranslational modifica-
tion in cells that influences many aspects of cell physiology,
including apoptosis, cell migration, and cell proliferation [4–8].
The mammalian calpains comprise 14 family members, of
which calpains 1 and 2 are the best-characterized calpain
isoforms. Calpains 1 and 2 function as heterodimeric enzymes
composed of a unique large catalytic subunit (calpains 1 and 2)
associated with a common small regulatory subunit (calpain 4)
[9]. Several studies indicate that calpain 2 can localize to
integrin-associated adhesive structures [10,11]. Studies uti-
lizing pharmacological inhibitors and calpain knockout cells
indicate that calpain plays an important role in mediating the
dynamic regulation of focal adhesions required for cell motility
[4,5,12,13]. Further studies demonstrating calpain cleavage of
the actin regulator, RhoA, and the actin-binding proteins cor-
tactin, spectrin, and EZRIN suggest other mechanisms where-
by calpain may influence the actin cytoskeleton [14–17].
Oncogenic cell transformation is characterized by morpho-
logical changes often arising from adhesion loss and disruption
of the actin cytoskeleton, as well as deregulated growth control
and loss of anchorage dependence for cell proliferation. A role
for calpain activity during oncogenesis was first inferred from
studies indicating that calpains degrade several oncogene
products such as platelet-derived growth factor receptor,
c-Jun, c-Fos, c-Src, c-Mos, and epidermal growth factor re-
ceptor (EGF-R) [18–23]. These studies led to the suggestion
that calpain may play a general suppressive role in malignant
transformation. This antitumorigenic role is supported by stud-
ies indicating that calpain-mediated cleavage of protein kinase
C (PKC), a downstream effector for tumor-promoting phorbol
esters, inhibits malignant transformation [24]. Similarly, one
study has suggested a role for calpain 9 (nCL-4) in the
suppression of cell transformation [25].
As well as a potential antitumorigenic role, calpain also
degrades several tumor-suppressor proteins such as p53,
NF2, IKBa, and p107 [26–29]. Our recent work demonstrated
that in response to conditional mutants of v-Src, calpain
induces proteolytic cleavage of focal adhesion kinase (FAK),
contributing to focal adhesion disassembly, morphological
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transformation, and cell motility [4]. We further demonstrated
that calpain activity also contributes to cell cycle progression
and anchorage-independent growth of v-Src transformed
cells [30,31]. A recent study has also indicated that calpain
activity acquires unique regulatory roles in cells transformed
by SV40 large T antigen, promoting invasive behavior [32]. In
addition, the proto-oncogene EGF-R, which is upregu-
lated in several tumor types in association with enhanced
malignancy, promotes cell migration by extracellular regulat-
ed kinase/mitogen-activated protein kinase (ERK/MAPK)–
induced activation of calpain [33]. Furthermore, the Her-2/
neu oncogene, a member of the EGF-R family, promotes cell
survival and the transformed phenotype by activation of the
transcription factor, NFkB. Her-2/neu–induced activation of
NFkB is mediated by casein kinase II (CK2)–induced phos-
phorylation of the NFkB-binding partner and repressor IkB-a;
this phosphorylation event subsequently targets IkB-a for
degradation by calpain, thus leading to activation of NFkB
[34]. Taken together, these studies present indirect evidence
suggesting that calpain may have a general role in facilitating
cell transformation and tumorigenesis.
A recent in vivo study directly implicates a role for
calpain in tumor invasion, antisense-mediated suppression
of calpain 2 suppressed invasion of prostate carcinoma
cells [35]. Previous in vivo studies also suggest a role for
calpain during the development of other tumor types. For
example, increased calpain 1 mRNA expression levels in
renal cell carcinoma correlate with increased malignancy
[36], and calpain-mediated cleavage of the tumor-suppres-
sor protein, NF2, is associated with the development of
some schwannomas and meningiomas [27]. Also, elevated
calpain activity and calpain-mediated cleavage of cyclin E
occur in cells and tissues derived from breast tumors
[37,38], and calpain 1 activity is significantly elevated in
chronic lymphocytic leukemia (B-CLL) cells when com-
pared with nonmalignant cells [39]. In contrast to these
protumorigenic effects, the expression of calpain 9 is
downregulated in gastric cancer tissues and cell lines
[40]. This, together with evidence that depletion of calpain
9 by antisense RNA results in cell transformation and
tumorigenesis, implies that at least one calpain isoform
(calpain 9) may function as a tumor suppressor [25].
The aim of the present study was to definitively determine
the role of calpain activity during oncogenic transformation.
Our studies indicate that total cellular levels of calpain activity
are elevated during transformation induced by many onco-
genes, including v-Src, v-Jun, v-Myc, k-Ras and v-Fos, with
the greatest increase observed in v-Myc transformed cells.
We found that calpain-mediated proteolysis of focal adhesion
proteins was a common oncogenic event, although precise
cleavage events varied. We further demonstrate that calpain
inhibitors suppressed remodelling of focal adhesions, and
cell migration of cells transformed by v-Myc but not the v-Fos
oncoprotein. In addition, inhibition of calpain activity sup-
pressed anchorage-independent growth in cells transformed
by all the oncoproteins under study. These findings indicate
that calpain activity is generally required for full cellular
transformation induced by a variety of common oncoproteins.
Materials and Methods
Cell Culture
Primary chicken embryo fibroblasts (CEFs) were subcul-
tured as previously described [41]. Low-density cultures
were transfected with replication-competent avian retroviral
SFCV-v-src construct, encoding the temperature-sensitive ts
LA29 v-Src mutant [42]. Transfected CEFs were cultured at
the permissive temperature of 35jC until cells were uniformly
infected and expressed the ts v-Src protein. For analysis of
v-Src– induced transformation, cells were cultured at the
restrictive temperature (41jC) and then examined following
shift to the permissive temperature (35jC). ASV17 (v-Jun)
and MC29 (v-Myc) transformed CEFs were provided by
D. Gillespie. 208F fibroblasts are a subclone of the Rat-1
fibroblast cell line. v-Fos transformed cells were generated
by infection of 208F fibroblasts with v-Fos FBR-MuSv and
provided by B. Ozanne. Rat-1 fibroblasts were transformed
by expression of constructs of k-Ras that contained an
activating point mutation at codon 12 provided by W. Kolch.
v12K-ras and v-FosFBR transformed fibroblasts and paren-
tal controls were cultured in 1  DMEM supplemented with
10% fetal calf serum (FCS) and 2 mM L-glutamine.
Antibodies and Reagents
ERK inhibition studies were performed using the MEK
inhibitor, UO126 (Promega, Madison, WI). CEFs expressing
ts v-Src were preincubated with UO126 (50 mM) for 1 hour
prior to shift to 35jC and subsequently incubated at 35jC in
the presence of UO126 (50 mM). All other cells were
incubated with UO126 (50 mM) for the indicated time period.
Calpain inhibitor studies were performed using calpain
inhibitor 1 (N-acetyl-Leu-Leu-norleucinal, ALLN, 10 mM;
Calbiochem-Novabiochem Corp., San Diego, CA) and cal-
pain inhibitor 2 (ALLM, 10 mM; Calbiochem-Novabiochem
Corp.). Caspase inhibitor studies were carried out with
caspase inhibitor 1 (ZVAD-FMK, 100 mM; Calbiochem-
Novabiochem Corp.). Proteasome inhibition was performed
with the specific inhibitor, lactacystin (10 mM). Lysosomal
cathepsins were inhibited by ammonium chloride (NH4Cl,
10 mM). Lysosomal and nonlysosomal cathepsin B activi-
ties were inhibited by the cell-permeable cathepsin B inhib-
itor, CA-074-Me (10 mM; Calbiochem-Novabiochem Corp.).
Antibodies for Western blot detection and immunocytochem-
istry included FAK and paxillin (BD Pharmingen, San Diego,
CA), talin (Sigma, Poole, England), a-II spectrin (Santa Cruz,
Santa Cruz, CA), and anti–a-tubulin (Sigma). Anti–mouse
and anti–rabbit peroxidase-conjugated secondary antibod-
ies were purchased fromNewEngland Biolabs, Inc. (Beverly,
MA). Anti–goat peroxidase antibodies were from Sigma.
Calpain Activity Assays
Analysis of calpain activity in total cell lysates was per-
formed using a calpain activity assay kit from BIOvision, Inc.,
(Mountain View, CA) according to the manufacturer’s instruc-
tions. The calpain activity kit contains a fluorogenic peptide
calpain substrate (Ac-LLY-AFC), lysis buffer, and reaction
buffer. Briefly, cells are lysed in lysis buffer for 20 minutes at
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4jC. Clarified cell lysates are then incubated with substrate
and reaction buffer for 1 hour at 37jC in the dark. Upon
cleavage of substrate, the fluorogenic portion (AFC)
releases yellow-green fluorescence at a wavelength of
505 nm following excitation at 400 nm. Fluorescence
emission was measured by a standard fluorimeter. For
each sample, control reactions were performed in the
presence of 5 mg of recombinant calpastatin (Calbiochem-
Novabiochem Corp.) to monitor any calpain-independent
proteolysis of fluorogenic peptide. Values from control
reactions were subtracted from total activity values to
specifically determine calpain activity for each sample.
Results are expressed as relative fluorescence units per
microgram of protein lysate. Analysis of calpain activity in
live cells was performed by incubation with the cell-perme-
able fluorogenic calpain substrate, BOC-LM-CMAC
(Molecular Probes, Inc., Eugene, OR). BOC-LM-CMAC con-
tains a fluorogenic subunit and a quencher subunit. Upon
cleavage by calpain, the fluorogenic portion separates from
the quencher, resulting in an increase in fluorescence emis-
sion. Cells were incubated with BOC-LM-CMAC (50 mM) for
20 minutes. Calpain-mediated cleavage of BOC-LM-CMAC
resulting in increased fluorescence was visualized by confo-
cal microscopy (magnification,  400).
Protein Immunoblotting
Cells were washed twice with phosphate-buffered
saline (PBS) and lysed in lysis buffer (10 mM Tris, pH
7.4, 150 mM NaCl, 0.5% NP40, 1 mM EDTA, 1 mM EGTA,
1 mMDTT, 0.5 mMNaF, 10 mM b-glycerophosphate, 10 mM
Na4P2O7, 100 mM NaVO4, with protease inhibitors, 1 mM
PMSF, 10 mg/ml leupeptin, and 10 mg/ml aprotinin). Lysates
were clarified by high-speed centrifugation at 4jC, supple-
mented with sodium dodecyl sulfate (SDS) sample buffer
and separated by 10% SDS polyacrylamide gel electropho-
resis (PAGE), and immunoblotted with specific antibodies.
Immunocytochemistry
Cells were cultured on permanox plastic chamber slides
(Nalge Nunc International, Naperville, IL). Cells were fixed in
3.7% formaldehyde for 10 minutes at room temperature,
permeabilized in 0.5% NP40 in PBS for 10 minutes at room
temperature, and washed serially in PBS, 0.15 M glycine/
PBS + 0.02% NaN3, and PBS. Cells were blocked in 10%
FCS/PBS prior to 1-hour incubation at room temperature
with the primary antibody, anti-paxillin (BD Pharmingen).
Primary antibody incubation was followed by several washes
in PBS and subsequent incubation with fluorescein isothio-
cyanate (FITC)–conjugated secondary antibodies (Jackson
Laboratories, West Grove, PA). Actin cytoskeleton was
monitored by staining with FITC-conjugated phalloidin
(Sigma). Immunostaining of cells was analyzed by confo-
cal microscopy (magnification,  1000).
Wound Healing Migration Assay
A total of 2  105 CEFs, nontransformed or expressing
ts v-Src, v-Jun, or v-Myc, was cultured at 41jC in 60-mm
dishes until 70% to 80% confluent. The cell monolayers were
wounded by scoring with a sterile micropipette tip and cul-
tures were incubated at 41jC (or 35jC in the case of CEF
expressing ts v-Src) for a further 12 hours in the absence or
presence of a panel of protease inhibitors at concentrations
described above. A total of 2  105 v12k-Ras and v-Fos
transformed cells and nontransformed rat-1 and 208F paren-
tal cells was cultured at 37jC in 60-mm dishes until 70% to
80% confluent prior to scoring with a sterile micropipette tip
and subsequent culture at 37jC in the absence or presence
of protease inhibitors. Cells were fixed and stained with
Coomassie blue and analyzed by microscopy (magnifica-
tion,  50). For quantification of wound assays, three defined
areas along a wound were monitored 4, 8, and 12 hours
following wound generation. The width of the denuded wound
area remaining at these time points was measured and mean
values of the three wound areas for each culture condition
were calculated as percentage of wound closure.
Anchorage-Independent Growth Assay
Briefly, 60-mm bacterial culture dishes were coated with
0.5% base agar supplemented with normal CEF or rat
fibroblast culture medium. Transformed cells were preincu-
bated with or without calpain inhibitors ALLN or ALLM (10mM)
for 1 hour in suspension prior to the addition of an equal
volume of top layer agar consisting of 0.6% agar, double-
concentrated CEF or rat growth medium, and ALLN or
ALLM, where required. Following several days in culture,
top layer agar was overlaid with base agar supplemented
with culture media + ALLN or ALLM, where required.
Anchorage-independent growth was quantified as the num-
ber of cell colonies formed per high-power field.
Apoptosis Detection
Cell apoptosis of v-Myc transformed cultures was moni-
tored using the Annexin V FITC apoptosis detection kit I (BD
Pharmingen) as per manufacturer’s instructions. Briefly,
v-Myc transformed cells were cultured under low serum
conditions either untreated or incubated with calpain inhib-
itors (ALLN and ALLM), proteasome inhibitor (lactacystin),
cathepsin inhibitors (ammonium chloride and CA-074-Me),
or caspase inhibitor (ZVAD) for 18 hours at concentrations
indicated above. Cells were washed twice with cold PBS and
resuspended in binding buffer. Cells were then incubated
with FITC-conjugated Annexin V and propidium iodide prior
to analysis by flow cytometry.
Results
Total Cellular Calpain Activity Is Elevated during Oncogenic
Transformation
Recent studies demonstrate that calpain acquires novel
regulatory roles in the presence of SV40 large T antigen [32]
and contributes to transformation mediated by the Her-2/neu
oncogene [34]. Our studies have shown that calpain-
mediated cleavage of FAK and, consequently, focal adhesion
turnover contribute to v-Src– induced morphological trans-
formation and anchorage-independent growth [4,30]. To
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determine whether calpain protease is generally modulated
during oncogenic transformation, we have employed a cal-
pain activity assay that utilizes a synthetic fluorogenic sub-
strate to monitor total levels of calpain activity in cell extracts.
To monitor and examine the role of calpain activity in v-Src
transformed cells, we have used CEFs that express a condi-
tional temperature-sensitive v-Src mutant (ts v-Src). When ts
v-Src CEFs are cultured at the restrictive temperature (41jC),
v-Src is inactive and the cells are not transformed; upon switch
of ts v-Src CEFs to the permissive temperature (35jC), v-Src is
activated and the cells undergo transformation [42]. We con-
sistently found that total levels of calpain activity in CEFs
expressing ts v-Src are increased during v-Src transformation
(Figure 1A). On average, calpain activity is 2.2-fold greater in
v-Src transformed cells when compared to their nontrans-
formed counterparts. In addition, we monitored calpain activity
in CEFs expressing constitutively active v-Jun or v-Myc com-
pared to normal primary CEFs. On average, calpain activity is
increased 1.8-fold in v-Jun transformed CEFs and around
11-fold in v-Myc transformed CEFs (Figure 1B). We also
monitored calpain activity in Rat-1 fibroblasts transformed with
the activating valine 12 k-Ras mutant (v12k-Ras) (Figure 1C)
and v-Fos (FBR) transformed 208F rat fibroblasts (Figure 1D),
and compared values with parental nontransformed counter-
parts. Calpain activity was elevated 3.2-fold and 1.5-fold,
respectively, in v12k-Ras (Figure 1C) and v-Fos (Figure 1D)
transformed cells. These data demonstrate for the first time
that the total cellular levels of calpain proteolytic activity are
modulated in cells transformed by, v-src, v-jun, v-myc, k-ras,
and v-fos oncogenes. In comparison to v-Myc transformed
cells, total levels of calpain activity in other transformed cells
are more modestly increased. However, it is possible that
calpain activity localized at specific subcellular sites is elevated
to agreater extent than canbedetected in total cell lysates. The
calpain activity assay used in this study does not distin-
guish between different calpain isoforms. Thus, the specific
calpain isoforms responsible for increased calpain activity
during oncogenic transformation remain to be determined.
Oncogene-Induced Calpain Activation Is Not Exclusively
Dependent on Upstream Regulation by ERK/MAPK
Activation of the ERK/MAPK signalling pathway occurs as
a consequence of v-Src and k-Ras activation [43,44]. Previ-
ous studies have demonstrated that EGF-R–induced activa-
tion of calpain is dependent upon ERK/MAPK activity [33,45].
To determine whether oncogene-induced activation of cal-
pain is also mediated by the ERK/MAPK pathway, we have
monitored levels of calpain activity in transformed cells
following treatment with the MEK inhibitor, UO126. UO126
treatment effectively suppressed p42 and p44 ERK/MAPK
Figure 1. Total cellular calpain activity is elevated during oncogenic transformation. Total cellular levels of calpain activity in cell extracts were determined by
monitoring fluorescence emission induced by cleavage of a specific fluorescent peptide substrate. Calpain activity levels were measured in (A). CEFs expressing ts
v-Src following culture at the restrictive temperature (v-Src off) and 24 hours at the permissive temperature (v-Src on) for v-Src activation. (B) Nontransformed (– ),
and v-Jun and v-Myc transformed CEFs. (C) Nontransformed (– ) and v12k-Ras transformed Rat-1 fibroblasts. (D) Nontransformed (– ) and v-Fos transformed
208F fibroblasts. Calpain activity was quantified by fluorimeter and results expressed as relative fluorescence units (RFU) per microgram of cell lysate. Data
represent the average values from three separate experiments.
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activity in all transformed cells as determined by immuno-
blotting with an antibody that specifically recognizes the
active phosphorylated forms of p44 and p42 ERK (results
not shown). Inhibition ofMEK suppressed both basal levels of
calpain activity in nontransformed cells and elevated calpain
activity in transformed cells. Our data indicate that UO126
reduces calpain activity levels in v-Src, v-Jun, and v-Fos
transformed cells to levels found in their nontransformed
counterparts (Figure 2, A, B, and E ). Thus, in response to
these oncogenes, ERK/MAPK plays an important role in
calpain activation. However, the MEK inhibitor only partially
suppressed calpain activity in v-Myc and v12k-Ras trans-
formed cells, indicating that a substantial proportion of cal-
pain activation in response to these oncogenes appears to be
independent of ERK/MAPK activity (Figure 2, C and D). This
result is surprising as the major effector pathway activated in
k-Ras transformed cells is ERK/MAPK, which, as mentioned,
is now recognized as a major calpain activator [33,45].
Our previous studies demonstrated that in response to
v-Src activation, calpain 2 protein levels are upregulated in
Figure 2. Oncogene-induced calpain activation is not exclusively dependent on upstream regulation by ERK/MAPK. The influence treatment with the MEK 1
inhibitor, UO126 (50 M, 6 hours), upon oncogene-induced calpain activation was monitored in (A). CEFs expressing ts v-Src following culture at the restrictive
temperature (v-Src off) and 6 hours at the permissive temperature (v-Src on) for v-Src activation. (B) Nontransformed (– ) and v-Jun transformed CEFs. (C)
Nontransformed (– ) and v-Myc transformed CEFs. (D) Nontransformed (– ) and v12k-Ras transformed Rat-1 fibroblasts. (E) Nontransformed (– ) and v-Fos
transformed 208F fibroblasts. Calpain activity was monitored by incubating cell lysates with fluorogenic calpain substrate and quantified by fluorimeter. Results are
expressed as relative fluorescence units (RFU) per microgram of cell lysate. Data represent the average values from three separate experiments.
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parallel with calpain-mediated degradation of calpastatin
[30]. These results indicated that in v-Src transformed cells,
a positive feedback loop mechanism operates, whereby
calpain degrades its own inhibitor, calpastatin. In contrast to
v-Src transformed cells, calpain 2 protein levels are not
significantly elevated in other transformed cells when com-
pared with normal counterparts, and no evidence of calpain-
mediated cleavage of calpastatin can be detected in v-Jun,
v-Myc, v12k-Ras, or v-Fos transformed cells (results not
shown). These data indicate that in contrast to v-Src trans-
formed cells, elevated calpain activity in v-Jun, v-Myc,
v12k-Ras, and v-Fos cells is not the result of calpain-mediated
degradation of calpastatin, demonstrating that although cal-
pain activity is enhanced by all the oncoproteins,mechanisms
of activation are distinct and may be oncogene-specific.
Calpain Activity in Live Cells Is Repressed by Treatment
with Calpain Inhibitors but Not Other Protease Inhibitors
To begin to understand the functional significance of
elevated calpain activity in different transformed cells, we
have applied the use of a panel of protease inhibitors. ALLN
and ALLM both selectively inhibit calpain protease activity
[46–48]. ALLN has also previously been demonstrated to
inhibit the proteolytic activity of cathepsins B and L and the
proteasome, whereas ALLM can also inhibit cathepsin B and
L activity. To ensure that phenotypic effects resulting from
treatment with ALLN and ALLM are specifically due to
calpain inhibition, we have also treated cells with the specific
proteasome inhibitor, lactacystin [49]; an inhibitor of all
lysosomal cathepsins, ammonium chloride [50,51]; and a
cell-permeable inhibitor of cathepsin, B (CA-074-Me) [52]. To
demonstrate that only the calpain inhibitors, but not inhibitors
of the other proteases, suppress calpain activity, we have
monitored calpain activity in live cells following treatment with
the panel of protease inhibitors. Cells were pretreated for 3
hours with the calpain inhibitors, ALLN and ALLM (10 mM);
the proteasome inhibitor, Lactacystin (Lacta, 10 mM); the
cathepsin inhibitors, ammonium chloride (NH4Cl, 10 mM)
and CA-074-Me (10 mM); and the broad caspase inhibitor,
ZVAD (100 mM), prior to loading with the cell-permeable
fluorogenic calpain substrate, BOC-LM-CMAC. Upon cleav-
age by calpain inside the cell, BOC-LM-CMAC emits fluo-
rescence. Fluorescence intensity of cells relating to calpain
activity can be visualized by confocal microscopy. Our
results demonstrated that only the calpain inhibitors, ALLN
and ALLM, but not the other protease inhibitors suppressed
calpain activity in nontransformed and v-Myc transformed
CEFs and also nontransformed 208F and v-Fos transformed
208F cells (Figure 3). Similar results were also obtained for
v-Src and v-Jun transformed CEFs and nontransformed and
v12k-Ras transformed Rat-1 cells (results not shown).
These results demonstrate that the calpain inhibitors,
ALLN and ALLM, effectively impair calpain activity in all
nontransformed and transformed cells, whereas inhibition
of the proteasomes, cathepsins, or caspases has no signif-
icant effect on calpain activity. The BOC assay also demon-
strates a visible increase in fluorescence intensity relating to
calpain activity in v-Myc transformed cells compared with
nontransformed CEFs (Figure 3). This result confirms our
previous observation demonstrating a significant upregula-
tion of calpain activity in cell extracts from v-Myc transformed
cells (Figure 1B).
Calpain-Mediated Regulation of Focal Adhesions and
the Actin Cytoskeleton during Oncogene-Induced Cell
Transformation
Our previous studies demonstrate that calpain activity
promotes focal adhesion turnover and loss of actin stress
fibers in v-Src transformed cells, thereby contributing to
morphological transformation andmigration [4]. To determine
whether oncogene-induced calpain activity also modulates
cell structural changes (i.e., morphological transformation)
induced by other oncoproteins, we examined cell morphol-
ogy, focal adhesion, and actin stress fibers in v-Jun, v-Myc,
v12k-Ras, and v-Fos transformed cells with and without
treatment with the calpain inhibitor, ALLN. The most striking
effect with ALLN treatment was observed in v-Myc trans-
formed cells where ALLN promoted cell attachment and
spreading (Figure 4A). ALLN treatment also suppresses the
high levels of cell detachment of v-Myc transformed cells,
thus v-Myc transformed cell cultures treated with ALLN
shown in Figure 4 appear more dense. In contrast, ALLN
treatment did not revert the morphology of v-Fos trans-
formed cells (Figure 4B). ALLN treatment reverted the
v-Myc transformed cells from their small round phenotype
with punctate focal adhesions to a more spread morphology
with significant enlargement of focal adhesions (Figure 5A)
more similar in appearance to that of normal nontrans-
formed CEFs (not shown). ALLN treatment also enhanced
the appearance of actin stress fibers in v-Myc transformed
cells (Figure 5A). ALLN treatment had no influence on the
loss of focal adhesion structures and disruption of the actin
cytoskeleton in v-Fos transformed cells (Figure 5B ).
Treatment with the proteasome inhibitor, lacatacystin
(Figure 4), or the cathepsin inhibitors, ammonium chloride
and CA-074-Me (results not shown), did not revert the
phenotype of any of the transformed cells, implying that the
ability of ALLN treatment to suppress v-Myc–induced cell
rounding, focal adhesion remodelling, and loss of actin stress
fibers is mediated by the inhibition of calpain activity. Al-
though focal adhesion loss andmorphological transformation
of v-Jun and v12k-Ras transformed cells are more subtle than
that observed for v-Myc or v-Fos transformed cells, calpain
inhibitors also promoted enhanced staining of paxillin at focal
adhesions in v12k-Ras and v-Jun transformed fibroblasts
(results not shown), suggesting that calpain inhibitors sup-
press the morphological effect of these oncoproteins, too.
Oncogene-Induced Calpain-Mediated Cleavage of FAK,
Talin, and Spectrin
Our data above (Figures 4 and 5) suggest that elevated
calpain activity plays a significant role in focal adhesion
remodelling and morphological transformation induced by
a variety of specific oncoproteins. To determine whether
elevated calpain activity in transformed cells resulted in
proteolytic cleavage of calpain substrates known to regulate
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Figure 3. Calpain activity in transformed cells is repressed by treatment with calpain inhibitors but not other protease inhibitors. Nontransformed and v-Myc
transformed CEFs and nontransformed and v-Fos transformed 208F rat fibroblasts were preincubated with calpain inhibitors (ALLN and ALLM), proteasome
inhibitor lactacystin (Lacta.), lysosomal cathepsin inhibitor (NH4Cl), cathepsin B inhibitor (CA-074-Me), and caspase inhibitor (ZVAD). Cells were preincubated with
protease inhibitors for 3 hours prior to incubation with the cell-permeable calpain substrate, BOC-LM-CMAC. Fluorescence intensity corresponding to calpain
activity was visualized by confocal microscopy (magnification, 400).
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Figure 4. Calpain inhibitors repress morphological transformation of cells transformed by v-Myc but not v-Fos. Phase contrast images (magnification, 200) of (A)
nontransformed CEFs and v-Myc transformed CEFs treated with calpain inhibitor (ALLN) or proteasome inhibitor (lactacystin). (B) Phase contrast images of
nontransformed 208F rat fibroblast and v-Fos transformed 208F cells treated with calpain inhibitor (ALLN) or proteasome inhibitor (lactacystin).
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Figure 5. Calpain-mediated regulation of focal adhesions and the actin cytoskeleton during transformation induced by v-Myc and v-Fos. (A) v-Myc transformed
CEFs or (B) v-Fos transformed rat fibroblasts were treated with the calpain inhibitor (ALLN, 10 M) for 18 hours. Focal adhesion structures were analyzed by
immunostaining with anti-paxillin antibody. The actin cytoskeleton was monitored by incubation with FITC-labeled phalloidin. Anti –paxillin- and phalloidin-stained
cells were analyzed by confocal microscopy. Scale bar = 25 m.
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focal adhesions and cell morphology, we examined the
protein levels of three well-characterized calpain sub-
strates, FAK, talin, and spectrin. FAK and talin are two
components of focal adhesion complexes that influence the
integrity and turnover of focal adhesions [53,54]. In addi-
tion, FAK plays a role in the transmission of signals by focal
adhesions to downstream signalling pathways [55]. Spec-
trin is an actin-binding protein that plays a role in maintain-
ing organization of the plasma membrane-proximal actin
cytoskeleton [56]. Previous studies have shown that FAK is
proteolytically cleaved by calpain, giving rise to a 95-kDa
N-terminal fragment [57,58]. As previously reported [4],
FAK is proteolytically cleaved extensively in v-Src trans-
formed cells (Figure 6A). In v-Myc transformed cells, an
anti–N-terminal FAK antibody detects a clear 95-kDa frag-
ment of FAK; however, no significant loss in levels of native
Figure 6. Oncogene-induced calpain-mediated cleavage of FAK, talin, and spectrin. (A) Total cell lysates were prepared from v-Src, v-Jun, v-Myc, v12k-Ras, and
v-Fos transformed cells and their nontransformed counterparts. Lysates were separated by SDS-PAGE and immunoblotted with antibodies against the calpain
substrates, FAK, talin, and a II spectrin. a-Tubulin immunoblots were performed as a control for protein loading. Molecular weight sizes of native protein and
proteolytic fragments are indicated. (B) Total cell lysates were prepared from v-Myc transformed cells that were untreated (control, C) or treated for 18 hours with a
calpain inhibitor (+ALLN), a proteasome inhibitor lactacystin (+Lacta), and a caspase inhibitor (+ZVAD). Lysates were separated by SDS-PAGE and immunoblotted
with antibodies against FAK, talin, a II spectrin, and a-tubulin.
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FAK is observed (Figure 6A), which suggests that proteo-
lysis of FAK may be compensated for by increased resyn-
thesis so that steady-state levels are not impaired.
Appearance of the 95-kDa FAK fragment is also slightly
upregulated in v12k-Ras transformed cells, but again no
significant loss in levels of native FAK protein was ob-
served. In contrast, proteolytic cleavage of FAK appears
to be decreased below basal levels in v-Jun transformed
cells and is not clearly observed in v-Fos transformed cells.
Previous studies have shown that talin is proteolytically
cleaved by calpain, giving rise to a 190-kDa N-terminal
fragment [59], and spectrin is cleaved by calpain, giving rise
to a 150-kDa fragment [60]. We demonstrate the appear-
ance of the 190-kDa talin cleavage product and the 150-
kDa spectrin cleavage product in v-Myc and v12k-Ras
transformed cells. No significant cleavage of talin or spec-
trin could be observed in either v-Src, v-Jun, or v-Fos
transformed cells (Figure 6A). These studies indicate that
a different spectrum of calpain substrates is cleaved at
focal adhesions during transformation by distinct onco-
genes. In keeping with our data demonstrating a lack of
morphological reversion upon treatment of v-Fos cells with
calpain inhibitors, no significant cleavage of any of the
above calpain substrates can be detected in v-Fos trans-
formed fibroblasts.
Consistent with our data (Figure 1) demonstrating that
v-Myc transformed cells had the highest levels of calpain
activity, proteolytic cleavage of all three calpain substrates
examined (FAK, talin, and spectrin) was most clearly and
consistently observed in v-Myc transformed cells (Figure 6A).
To determine whether the proteolytic cleavage of FAK, talin,
and spectrin in v-Myc transformed cells is specifically due to
calpain activity, v-Myc transformed cells were treated with
inhibitors against the calpains (ALLN), a specific proteasome
inhibitor (lactacystin), and the broad caspase inhibitor
(ZVAD) (Figure 6B). Proteolytic cleavage of FAK in v-Myc
transformed cells was inhibited by both the calpain and the
caspase inhibitors (Figure 6B). In contrast, talin and spectrin
cleavage is only significantly blocked by the calpain inhibitor
(Figure 6B). Previous studies indicate that FAK can be
proteolytically cleaved by caspases during apoptotic cell
death, resulting in proteolytic fragments similar in size to
those generated by calpain cleavage [61,62]. Both calpain
and caspase inhibitors suppressed FAK cleavage
(Figure 6B), suggesting that calpains and caspases both
cleave FAK in v-Myc transformed cells; alternatively, cal-
pains may promote FAK cleavage indirectly by promoting
apoptosis and caspase activation. However, our data argue
against the second possibility as the caspase inhibitor,
ZVAD, only partially suppresses FAK cleavage and is con-
sistently less effective than the calpain inhibitor, ALLN
(Figure 6B), suggesting that in the absence of caspase
activity, calpain can still cleave FAK in v-Myc transformed
cells. Consistent with the fact that talin has not been identi-
fied as a caspase substrate and caspase-mediated cleavage
of a II spectrin results in the generation of a distinct 120-kDa
fragment [60], calpain inhibitors, but not caspase inhibitors,
suppressed talin and a II spectrin cleavage in v-Myc trans-
formed cells. These results indicate that talin and spectrin
cleavage in v-Myc transformed cells is mediated by calpain
activity with no contribution from caspases.
The Motility of v-Src, v-Myc, v-Jun , v12k-Ras, but Not v-Fos
Transformed Cells, Is Dependent on Calpain Activity
To determine whether modulated activities of calpain
influenced the motility of cells transformed by different onco-
genes, we performed wound repair assays in the presence
of selective protease inhibitors and compared with untrans-
formed control cells. The inhibitors used were calpains
inhibitors (ALLN and ALLM), the specific proteasome in-
hibitor (lactacystin), an inhibitor of lysosomal cathepsins
(ammonium chloride, NH4Cl), the cathepsin B inhibitor (CA-
074-Me; results not shown), and the caspase inhibitor,
ZVAD, which do not influence calpain activity in these cells
(Figure 3). Only the calpain inhibitors, ALLN and ALLM,
suppressed the motility of v-Src, v-Myc, and v-Jun trans-
formed cells into the denuded area of the monolayer
(Figure 7A). The calpain inhibitors also suppressed the
motility of nontransformed CEFs into the wounded area
(Figure 7A). These results indicate that the selective calpain
inhibitors, ALLN and ALLM, impair cell migration and that
calpain activity is required for the migration of both non-
transformed and v-Src, v-Myc, and v-Jun (to a smaller extent)
transformed cells. The calpain inhibitors also suppressed the
movement of v12k-Ras transformed cells and their nontrans-
formed Rat-1 counterparts into the wound (Figure 7B). In
contrast to all other nontransformed and transformed cell
types examined, migration of v-Fos transformed cells into the
denuded area was not retarded by treatment with calpain
inhibitors (Figure 7B). The migration of v-Myc and v-Fos
transformed cells into the denuded area following treatment
with the calpain inhibitor, ALLN, was quantified at sequential
time points by microscopy of three defined areas of the
wound (1, 2, and 3) (Figure 8, A–C). Cells suspected of
floating into wound area were discounted; thus, only migra-
tion of cells from the wound periphery was quantified. These
results further confirm that in contrast to v-Myc transformed
cells, themotility of v-Fos transformed cells is not suppressed
by the calpain inhibitor, ALLN (Figure 8C). This indicates that
v-Fos transformed cells have acquired mechanisms of cell
locomotion that are independent of calpain proteolytic activity
and therefore distinct from their nontransformed counterparts
and cells transformed by other oncoproteins.
Calpain Inhibitors Repress Anchorage-Independent Growth
of v-Src, v-Jun, v-Myc, v12k-Ras, and v-Fos Transformed
Cells
A hallmark of all transformed cells is their ability to grow
in an anchorage-independent manner. Our previous stud-
ies indicate that calpain activity is required for anchorage-
independent growth of v-Src transformed cells [30]. In
contrast, previous studies on NIH 3T3 cells demonstrated
that the calpain inhibitor, ALLN, promoted anchorage-inde-
pendent growth [63]. Our data in this present study dem-
onstrate that treatment with ALLN or ALLM significantly
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Figure 7. The motility of v-Src, v-Myc, v-Jun, v12k-Ras, but not v-Fos transformed cells, is dependent on calpain activity. (A) A wound was generated in a
subconfluent monolayer of v-Src, v-Jun, and v-Myc transformed CEFs and nontransformed CEFs. Wound size was initially recorded at time 0 (T0), and cells were
then further incubated for 12 hours in the absence (control) or presence of the calpain inhibitors, ALLN and ALLM; the proteasome inhibitor, lactacystin; the
lysosomal cathepsin inhibitor, ammonium chloride (NH4Cl); and the caspase inhibitor, ZVAD. (B) Denuded wounds were also generated in subconfluent
monolayers of v12k-Ras and nontransformed Rat-1 fibroblasts and v-Fos and nontransformed 208F fibroblasts. As above, wound size was recorded at time 0 and
12 hours following culture in the absence or presence of the panel of protease inhibitors described in (A). White lines represent the initial denuded area.
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suppressed anchorage-independent growth of v-Src,
v-Jun, and v-Myc transformed CEFs and also v12k-Ras
transformed Rat-1 fibroblasts (Figure 9, A and B). ALLN
and ALLM also slightly reduced anchorage-independent
growth of v-Fos transformed rat fibroblasts. These data
imply that calpain activity is required for optimal onco-
gene-induced anchorage-independent growth of the trans-
formed cells examined in this study.
Calpain Activity Contributes to v-Myc–Induced Apoptosis
One hallmark of Myc-induced transformation is high
levels of apoptotic cell death [64]. Calpain activity has
Figure 7. (Continued)
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previously been shown to play a proapoptotic role by
activation of caspases 3 and 12 [7,65] and cleavage of
proapoptotic Bax and Bid proteins [66,67]. Conversely,
calpain-mediated cleavage of p53 [68] and caspases 7
and 9 [69] suppresses apoptosis. Our data (Figures 1
and 6) suggest that elevated calpain activity in v-Myc
Figure 8. Quantification of v-Myc and v-Fos transformed cell motility in presence of the calpain inhibitor, ALLN. A denuded wound area was generated in a
subconfluent monolayer of (A) v-Myc transformed cells or (B) v-Fos transformed cells. Three defined areas (1, 2, and 3) along the wound were monitored 4, 8, and
12 hours following wound generation in cultures untreated or treated with ALLN (10 M). White lines represent the remaining denuded area. (C) Data from (A) and
(B) are expressed as the percentage of wound closure at 4, 8, and 12 hours following wound generation and represent mean values from three separate areas of
wound in each sample.
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transformed cells may cooperate with caspases to promote
proteolytic cleavage of FAK. To demonstrate whether ele-
vated calpain activity also contributes to v-Myc induced cell
apoptosis, we monitored apoptosis in serum-starved v-Myc
transformed cells treated with two separate calpain inhibi-
tors, ALLN and ALLM, as well as proteasome, cathepsin, and
caspase inhibitors. Apoptotic cell death was measured using
an Annexin V FITC detection kit. Both ALLN and ALLM
treatment reduced the levels of apoptotic cell death in
v-Myc transformed cell cultures (Figure 10). As expected,
the caspase inhibitor, ZVAD, also suppressed apoptosis,
whereas the proteasome inhibitor, lactacystin, only had a
mild suppressive effect on v-Myc induced apoptosis and the
cathepsin inhibitors, ammonium chloride and CA-074-Me,
had no effect on v-Myc–induced apoptosis (Figure 10).
Discussion
Previous studies present a conflicting role for the calpain
family of proteolytic enzymes during oncogenic cell trans-
formation. Antisense-mediated suppression of calpain 9
(formally nCL-4) promoted anchorage-independent growth
of NIH 3T3 cells [25]. In addition, treatment with calpain
inhibitors and overexpression of calpastatin also promoted
anchorage-independent growth of NIH 3T3 cells [24,63].
These studies suggested that calpain activity suppresses
cellular transformation. Curiously, in the second study by
Hiwasa et al. [24], overexpression of calpain 4, the small
regulatory domain required for both calpain 1 and calpain 2
activity [12], also promoted anchorage-independent growth
of NIH 3T3, suggesting that calpain may also promote
cellular transformation. Using a combination of approaches
including calpain inhibitors, calpastatin overexpression, and
calpain 4 KO cells, we previously demonstrated that calpain
activity promotes morphological transformation and anchor-
age-independent growth of v-Src transformed fibroblasts
[30]. Other studies suggest that calpain-mediated cleavage
of IkBa also contributes to anchorage-independent growth
of breast cancer cells [34] and, in SV40-transformed cells,
calpain acquires new roles that promote invasion [32].
From the above studies, the precise role of calpain during
cell transformation remains a controversial issue. The aim of
this study was to address in some detail the requirement for
calpain for different aspects of the transformed phenotype
and to examine the regulation and role of calpain activity
during cellular transformation induced by a number of well-
characterized oncogenes that have previously been demon-
strated to play important roles in cancer development. Using
a synthetic fluorogenic substrate specific for calpain, we
monitored total cellular levels of calpain activity in trans-
formed cells. Our studies demonstrate that calpain activity is
significantly upregulated in cells transformed by v-Src, v-Jun,
v-Myc, v12k-Ras, and v-Fos when compared with matched
nontransformed counterparts. The greatest increase in cal-
pain activity was observed in v-Myc transformed cells, which
was approximately 11-fold higher than levels found in their
nontransformed counterparts. Although ERK/MAPK signal-
ling is important for EGF-R–induced activation of calpain
[33,45], our results indicate that in response to the specific
oncogenes v12k-Ras and v-Myc, activation of calpain can
occur independently of ERK/MAPK signalling. In contrast,
elevated calpain activity in v-Src, v-Jun, and v-Fos trans-
formed cells is strongly dependent on ERK/MAPK signalling.
Thus, the influence that ERK/MAPK signalling has on regu-
lating oncogene-induced calpain activation varies between
different oncogenes. These results indicate that different
modes of regulating calpain activity may operate in cells
transformed by distinct oncogenes.
We have previously reported that increased protein
synthesis of calpain 2 and calpain-mediated cleavage of
calpastatin may promote calpain activity in v-Src trans-
formed cells. In addition, caspase-mediated cleavage of
calpastatin can promote calpain activity during cell apopto-
sis [70]. The calpain 2 gene contains an AP-1–binding
Figure 8. (Continued)
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Figure 9. Calpain inhibitors repress anchorage-independent growth of v-Src, v-Jun, v-Myc, v12k-Ras, and v-Fos transformed cells. (A) v-Src, v-Jun, v-Myc, v12k-
Ras, and v-Fos transformed cells were cultured in soft agar in the absence (control) or presence of the calpain inhibitors (ALLN) or (ALLM). Phase pictures
record colony formation 14 days following cell seeding. (B) Colony formation was quantified by counting the number of colonies per high-power field
(magnification, 25).
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Figure 10. Calpain activity contributes to v-Myc– induced apoptosis. v-Myc transformed cells were incubated in serum-depleted media for 24 hours without
treatment, or treatment with the calpain inhibitors, ALLN and ALLM; the proteasome inhibitor, lactacystin; the lysosomal cathepsin inhibitor, NH4Cl; the cathepsin B
inhibitor, CA-074-Me; or the caspase inhibitor, ZVAD. Cells were washed and dual-stained with FITC-conjugated Annexin V and propidium iodide to detect
apoptotic cells. (A) The proportion of viable (M1) and apoptotic (M2) cells in cultured populations was analyzed by flow cytometry. (B) Bar graph representing the
percentage of apoptotic cells in v-Myc transformed cell cultures following treatment with various protease inhibitors.
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motif, suggesting that calpain 2 may be transcriptionally
regulated by Fos and Jun oncoproteins [71]. Our data
indicate that calpain 2 protein levels are only slightly in-
creased in v-Jun and v-Myc transformed cells but are not
altered in v12k-Ras and v-Fos transformed cells (results not
shown). Calpastatin protein levels are also not modulated in
v-Jun and v-Myc transformed chick fibroblasts, and 110-
and 70-kDa calpastatin isoforms are not subject to cleavage
in v12k-Ras and v-Fos transformed cells (results not shown).
These data indicate that in contrast to v-Src transformed
cells, calpain-mediated degradation of calpastatin does not
account for elevated calpain activity in cells transformed by
other oncoproteins. Our data demonstrating that calpastatin
protein levels are maintained in v-Myc transformed cells
also rule out caspase-mediated cleavage of calpastatin as
the mechanism responsible for the high levels of calpain
activity in v-Myc transformed cells.
Several other regulatory mechanisms for controlling
calpain activity have previously been described, including
translocation to the plasma membrane and interaction with
phospholipids [72,73], modulation of intracellular calcium
levels [74], phosphorylation of calpastatin by PKC [75],
phosphorylation of calpain mediated by PKA [76], and
specific phosphorylation of calpain 2 on serine by ERK/
MAPK [77]. To examine the phosphorylation status of
calpain 2 following transformation, we immunoprecipitated
calpain 2 from lysates extracted from nontransformed and
transformed cells and then immunoblotted with an anti-
phosphoserine antibody. Our studies could not detect any
serine phosphorylation of calpain 2 in either any of the
nontransformed or transformed cells studied. However, this
may be a result of the lack of sensitivity of the reagents
used to detect serine phosphorylation. Further detailed
studies will be required to determine whether any of the
above mechanisms contributes to elevated calpain activity
during oncogene-induced cell transformation.
Morphological transformation induced by oncogenes is
often characterized by loss of focal adhesions, and actin
stress fibers and many calpain substrates are focal adhesion
proteins. We have previously shown that calpain inhibitors
suppress v-Src– induced morphological transformation [4].
Here we show that calpain inhibitors promote cell spreading
and the reappearance of large focal adhesions in v-Myc
transformed cells (and also in v12k-Ras and v-Jun cells)
reverting the morphological phenotype to that which is more
similar to their nontransformed counterparts. In contrast,
calpain inhibitors have no effect on the morphological tran-
sition of v-Fos transformed cells, which also includes the loss
of focal adhesions and disruption of the actin cytoskeleton.
To gain insights into how elevated calpain activity may
contribute to oncogene-induced morphological transforma-
tion, we monitored the proteolytic cleavage of key sub-
strates. In this study, we show for the first time that talin
and a II spectrin are proteolytically cleaved by calpain in
v-Myc transformed cells. Talin is an actin-binding protein that
is also found at focal adhesion sites and links integrins to the
actin cytoskeleton [78]. Calpain-mediated cleavage of talin
has been proposed to contribute to both focal adhesion
disassembly [12,58] and the clustering and activation of
integrins [79]. Spectrins are also actin-binding proteins that
are components of the membrane cytoskeleton; thus, cal-
pain-mediated cleavage of a II spectrin has been proposed
to play an important role during membrane skeleton remod-
elling [80]. Thus, calpain-mediated cleavage of talin and a II
spectrin may contribute to focal adhesion remodelling and
morphological transformation of v-Myc transformed cells.
Calpain activity also contributes to FAK cleavage in v-Myc
cells and to a smaller extent in v12k-Ras cells, and may also
contribute to morphological changes in a similar manner to
the role of calpain-mediated cleavage of FAK previously
described in v-Src transformed cells [4,30]. Previous studies
demonstrate that Src-induced phosphorylation of proteins
such as cortactin, spectrin, and the NR2 subunits of NMDA
receptors influence their ability to act as calpain substrates
[14,80,81]. These studies indicate that calpain substrates in
v-Src transformed cells may be different from substrates
found in other cell types. Our data demonstrating that talin
and a II spectrin cleavage is restricted to v12k-Ras and v-Myc
transformed cells further indicate that calpain-mediated
cleavage of specific substrates varies between transformed
cells depending on the oncogene responsible for transfor-
mation. Thus, it is possible that calpain may play different
roles in malignant transformation depending on the sub-
strates that are targeted for calpain cleavage.
Treatment with inhibitors that block calpain proteolytic
activity, but not other cellular proteolytic inhibitors, sup-
presses the migration of all the transformed cells studied
with the exception of v-Fos transformed cells. Uniquely,
v-Fos transformed cells have acquired mechanisms that
are independent of calpain activity, which promote focal
adhesion loss and cell motility. The elucidation of how
focal adhesions and cell motility are influenced by the Fos
oncoprotein may identify novel-selective therapeutic tar-
gets for tumor invasion where aberrant activation of AP-1
transcription factor complexes play a causative role. Cal-
pain inhibition also suppressed the migration of nontrans-
formed cells indicating that calpain activity in normal cells
is required for cell motility. However, it remains possible
that elevated calpain activity induced by v-Jun, v-Myc,
v12k-Ras, and v-Src may contribute to an invasive phe-
notype of tumor cells in vivo.
Previous studies suggesting that calpain plays a nega-
tive role in permitting anchorage-independent growth have
utilized the cell-permeable calpain inhibitor ALLN. ALLN
was found to promote normal cell growth and anchorage-
independent growth of NIH3T3 mouse fibroblasts [63].
However, ALLN did not significantly influence normal cell
growth of Ras-transformed NIH 3T3 cells [24]. These
studies indicate that oncogene-induced transformation of
cells may alter the role of calpain activity in the normal
proliferative response and in anchorage-independent
growth. Our studies demonstrate that in contrast to these
NIH 3T3 studies, anchorage-independent growth of v-Src,
v-Jun, v-Myc, v12k-Ras, and v-Fos transformed cells is
suppressed by treatment with the calpain inhibitors, ALLN
and ALLM. These studies on the major oncogenic hallmark
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of transformation (anchorage-independent growth) indicate
that calpain is an important and general mediator of the
transformed cell phenotype.
Both v-Myc and c-Myc are potent inducers of apoptosis
[82,83]. Myc-induced cell cycle progression has been pro-
posed to sensitize transformed cells to apoptotic death;
however, recent evidence indicates that c-Myc sensitizes
cells to a wide range of proapoptotic stimuli that may not be
directly linked to the cell cycle [83]. It has been proposed that
the apoptotic function of Myc may have been developed as a
safeguard to allow the elimination of Myc-transformed cells;
however, in vivo, the apoptotic pathway may be suppressed
due to the availability of survival factors. Understanding the
mechanisms that mediate v-Myc–induced apoptosis has
particular importance because of its potential role in tumor
suppression. Conflicting roles for calpain activity in contrib-
uting to the promotion and suppression of apoptosis have
been proposed [7,65–69]. In this study, we demonstrate that
treatment with calpain inhibitors suppresses levels of apo-
ptotic cell death in v-Myc transformed cell cultures, indicating
that elevated calpain activity can be added to the list of
contributors to Myc-induced apoptosis.
In summary, this study demonstrates that elevated cal-
pain proteolytic activity in cells transformed by particular
oncogenes plays important roles in remodelling focal adhe-
sion structures that contribute to cell motility and also in
promoting anchorage-independent growth. Calpain plays a
positive role in promoting morphological transformation and
anchorage-independent growth of many transformed cells;
however, the calpain substrates and mechanisms by which
calpain achieves these effects vary depending on the onco-
protein responsible for transformation. Further studies are
required to identify the key calpain substrates that are
responsible for deregulated growth control and invasion of
tumor cells. Once specific roles for calpain activity have been
elucidated, targeting specific aspects of calpain activity may
represent novel therapeutic treatments that can be adminis-
tered to specific types of tumors depending on the oncogenic
events responsible for carcinogenesis. In contrast to the
majority of transformed cells studied, v-Fos induced mor-
phological transformation and the motility of v-Fos trans-
formed cells is independent of calpain activity, thus defining
the unique mechanisms acquired by v-Fos transformed cells
that promote cell motility and may identify further novel
therapeutic targets for tumor invasion.
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